Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b5 reductase activity

J Clin Pharmacol. 2012 Feb;52(2):272-8. doi: 10.1177/0091270010393343.
No abstract available

Keywords: Methemoglobin; N-acetylation; adverse drug reaction; arylamine.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Anti-Infective Agents / adverse effects*
  • Arylamine N-Acetyltransferase / genetics*
  • Cytochrome P-450 CYP2C19 / genetics
  • Cytochrome-B(5) Reductase / genetics*
  • Cytochromes b5 / genetics
  • Dapsone / adverse effects*
  • Haplotypes
  • Humans
  • Male
  • Methemoglobinemia / chemically induced*
  • Methemoglobinemia / genetics

Substances

  • Anti-Infective Agents
  • CYB5A protein, human
  • Dapsone
  • Cytochromes b5
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • CYB5R3 protein, human
  • Cytochrome-B(5) Reductase
  • Arylamine N-Acetyltransferase
  • NAT2 protein, human